Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
1996 2
1997 2
1998 2
2001 1
2004 1
2006 1
2007 2
2008 1
2009 1
2010 1
2012 2
2014 1
2015 1
2016 3
2017 3
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors.
Qin LY, Ruan Z, Cherney RJ, Dhar TGM, Neels J, Weigelt CA, Sack JS, Srivastava AS, Cornelius LAM, Tino JA, Stefanski K, Gu X, Xie J, Susulic V, Yang X, Yarde-Chinn M, Skala S, Bosnius R, Goldstein C, Davies P, Ruepp S, Salter-Cid L, Bhide RS, Poss MA. Qin LY, et al. Among authors: susulic v. Bioorg Med Chem Lett. 2017 Feb 15;27(4):855-861. doi: 10.1016/j.bmcl.2017.01.016. Epub 2017 Jan 10. Bioorg Med Chem Lett. 2017. PMID: 28108251
Wnt10b inhibits obesity in ob/ob and agouti mice.
Wright WS, Longo KA, Dolinsky VW, Gerin I, Kang S, Bennett CN, Chiang SH, Prestwich TC, Gress C, Burant CF, Susulic VS, MacDougald OA. Wright WS, et al. Among authors: susulic vs. Diabetes. 2007 Feb;56(2):295-303. doi: 10.2337/db06-1339. Diabetes. 2007. PMID: 17259372
Biologic-like In Vivo Efficacy with Small Molecule Inhibitors of TNFα Identified Using Scaffold Hopping and Structure-Based Drug Design Approaches.
Xiao HY, Li N, Duan JJ, Jiang B, Lu Z, Ngu K, Tino J, Kopcho LM, Lu H, Chen J, Tebben AJ, Sheriff S, Chang CY, Yanchunas J Jr, Calambur D, Gao M, Shuster DJ, Susulic V, Xie JH, Guarino VR, Wu DR, Gregor KR, Goldstine CB, Hynes J Jr, Macor JE, Salter-Cid L, Burke JR, Shaw PJ, Dhar TGM. Xiao HY, et al. Among authors: susulic v. J Med Chem. 2020 Dec 10;63(23):15050-15071. doi: 10.1021/acs.jmedchem.0c01732. Epub 2020 Dec 1. J Med Chem. 2020. PMID: 33261314
Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients.
Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, Porsbjerg CM, Girodet PO, Berger P, Kline JN, Chupp G, Susulic VS, Barnathan ES, Baribaud F, Loza MJ; Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study investigators. Silkoff PE, et al. Among authors: susulic vs. J Allergy Clin Immunol. 2017 Sep;140(3):710-719. doi: 10.1016/j.jaci.2016.11.038. Epub 2017 Jan 13. J Allergy Clin Immunol. 2017. PMID: 28089872 Clinical Trial.
Targeted disruption of the beta 3-adrenergic receptor gene.
Susulic VS, Frederich RC, Lawitts J, Tozzo E, Kahn BB, Harper ME, Himms-Hagen J, Flier JS, Lowell BB. Susulic VS, et al. J Biol Chem. 1995 Dec 8;270(49):29483-92. doi: 10.1074/jbc.270.49.29483. J Biol Chem. 1995. PMID: 7493988 Free article.
Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases.
Xie JH, Yamniuk AP, Borowski V, Kuhn R, Susulic V, Rex-Rabe S, Yang X, Zhou X, Zhang Y, Gillooly K, Brosius R, Ravishankar R, Waggie K, Mink K, Price L, Rehfuss R, Tamura J, An Y, Cheng L, Abramczyk B, Ignatovich O, Drew P, Grant S, Bryson JW, Suchard S, Salter-Cid L, Nadler S, Suri A. Xie JH, et al. Among authors: susulic v. J Immunol. 2014 May 1;192(9):4083-92. doi: 10.4049/jimmunol.1303239. Epub 2014 Mar 26. J Immunol. 2014. PMID: 24670803
Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study.
Loza MJ, Djukanovic R, Chung KF, Horowitz D, Ma K, Branigan P, Barnathan ES, Susulic VS, Silkoff PE, Sterk PJ, Baribaud F; ADEPT (Airways Disease Endotyping for Personalized Therapeutics) and U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome Consortium) investigators. Loza MJ, et al. Among authors: susulic vs. Respir Res. 2016 Dec 15;17(1):165. doi: 10.1186/s12931-016-0482-9. Respir Res. 2016. PMID: 27978840 Free PMC article.
Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study.
Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, Porsbjerg C, Girodet PO, Berger P, Kline JN, Khatri S, Chanez P, Susulic VS, Barnathan ES, Baribaud F, Loza MJ; ADEPT Investigators. Silkoff PE, et al. Among authors: susulic vs. Respir Res. 2016 Apr 23;17:43. doi: 10.1186/s12931-016-0360-5. Respir Res. 2016. PMID: 27107814 Free PMC article. Clinical Trial.
27 results